Patel Akash M, Berger Ian, Wileyto E Paul, Khalid Urooj, Torigian Drew A, Nachiappan Arun C, Barbosa Eduardo M, Gefter Warren B, Galperin-Aizenberg Maya, Gupta Narainder K, Simone Charles B, Haas Andrew R, Alley Evan W, Singhal Sunil, Cengel Keith A, Katz Sharyn I
Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
J Thorac Dis. 2017 Aug;9(8):2344-2349. doi: 10.21037/jtd.2017.07.86.
Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance imaging (MRI).
All MPM patients with intravenous (IV) contrast enhanced staging MRI between 2000-2016 at our institution were retrospectively selected for image analysis. Patients with incomplete imaging protocol and maximum pleural tumor thickness <1 cm were excluded. Quantitative measurements of tumor signal intensity were obtained on pre-contrast and post-contrast phases where MRI acquisition parameters were fixed. Using best-fit model curves, predicted maximum time points of enhancement were determined using a simulation of predicted values. Additionally, a qualitative assessment of tumor conspicuity was performed at all IV contrast time delays imaged. A statistical analysis assessed for correlation between qualitative lesion conspicuity and quantitative tumor enhancement.
Of the 42 MPM patients who had undergone staging MRI during the study period, 12 patients met the study criteria. Peak tumor enhancement was between 150 and 300 sec following IV contrast administration. Within this time window, 80% of patients are projected to have reached >80%, >85%, and >90% peak tumor enhancement. There was a statistically significant correlation between increasing tumor enhancement and subjective lesion conspicuity.
Optimal MPM enhancement on MRI likely occurs at a time delay between 2.5-5 min following IV contrast administration. Further study of delayed phase enhancement of MPM with dynamic contrast enhanced MRI is warranted.
恶性胸膜间皮瘤(MPM)的横断面成像可能会低估局部肿瘤侵犯的存在。由于准确分期对治疗的最佳选择至关重要,因此需要优化胸膜成像的技术。在此,我们评估了磁共振成像(MRI)上MPM增强的最佳时间。
回顾性选择2000年至2016年期间在我们机构接受静脉(IV)对比剂增强分期MRI检查的所有MPM患者进行图像分析。排除成像方案不完整且最大胸膜肿瘤厚度<1 cm的患者。在MRI采集参数固定的情况下,在对比剂前和对比剂后阶段获得肿瘤信号强度的定量测量值。使用最佳拟合模型曲线,通过预测值模拟确定预测的最大增强时间点。此外,在所有成像的IV对比剂时间延迟时对肿瘤的清晰度进行定性评估。进行统计分析以评估定性病变清晰度与定量肿瘤增强之间的相关性。
在研究期间接受分期MRI检查的42例MPM患者中,12例符合研究标准。静脉注射对比剂后,肿瘤增强峰值出现在150至300秒之间。在此时间窗口内,预计80%的患者肿瘤增强峰值将达到>80%、>85%和>90%。肿瘤增强增加与主观病变清晰度之间存在统计学显著相关性。
MRI上MPM的最佳增强可能发生在静脉注射对比剂后2.5至5分钟之间的时间延迟。有必要进一步研究动态对比增强MRI对MPM延迟期增强的作用。